Navigation Links
Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZeneca's SEROQUEL(R) XR

FREMONT, Calif., July 31 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, the generic version of AstraZeneca's SEROQUEL(R) XR, has been accepted for filing by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for SEROQUEL(R) XR containing a Paragraph IV certification, under the provisions of the Hatch- Waxman Act. Should its ANDA be approved by the FDA, Handa believes that its product will be entitled to 180 days of generic market exclusivity.

About Handa Pharmaceuticals, LLC

Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. For more information, please visit

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

SEROQUEL(R) and SEROQUEL(R) XR are registered trademarks of the AstraZeneca group of companies.

Contact: Stephen Cary of Handa Pharmaceuticals, LLC, +1-510-354-2888

SOURCE Handa Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
4. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
5. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
6. New Natural Product from Zurich Pharmaceuticals Downs Appetite
7. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
10. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
11. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... ... 2015 , ... December 1, 2015 -- InstantLabs is adding ... product line of food safety and seafood fraud prevention tools. , The new ... InstantLabs to offer fast, reliable species identification for the four most popular salmon. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first ... Annual Meeting from November 29 to December 4, 2015. , MED-TAB is ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, 2015 ... price per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) ... provides software engineering, infrastructure, as well as operations and sustainment support to the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)...  Athletic apparel company Tommie Copper , ... $1.35 million to settle Federal Trade Commission charges ... clothing would relieve severe and chronic pain and ... Tommie Copper,s proposed settlement with ... founder and chairman Thomas Kallish to ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... to a new market research report "Nucleic Acid Labeling ... Techniques (PCR, Nick Translation, Random Primer, In Vitro Transcription, ... to 2020", published by MarketsandMarkets, The global market is ... USD 1,271.8 Million in 2015, growing at a CAGR ...
Breaking Medicine Technology: